{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:29:16Z","timestamp":1788449356343,"version":"build-2803163510"},"reference-count":18,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and purpose<\/jats:title><jats:p>This study was undertaken to highlight neonatal Fc receptor inhibition (efgartigimod) as a valuable therapeutic option for patients with refractory seronegative myasthenia gravis (MG) and to emphasize the concept that seronegative MG is greatly constrained by the limitations of currently available diagnostic methods and therapeutic measures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We describe the first refractory, generalized MG (gMG) patient successfully treated with efgartigimod after testing negative on standard autoantibody detection tests.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our patient presented with severe fluctuating bulbar and generalized weakness, resulting in multiple myasthenic crises requiring intubation. After a 28\u2010year medical history of multiple failed lines of treatment, our patient was started on efgartigimod. Over five treatment cycles, a definite improvement in her clinical condition was observed (Myasthenia Gravis Foundation of America class: IIIb to IIb; MG\u2010Activities of Daily Living score: 11 to 0; MG\u2010Quality of Life 15 score: 30 to 0; Quantitative MG score: 28 to 6). Standard autoantibody detection tests failed to detect known pathogenic autoantibodies, but cell\u2010based assay (CBA) identified autoantibodies against clustered adult acetylcholine receptor (AChR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In light of recent approvals of efgartigimod by the European Medicines Agency and US Food and Drug Administration exclusively for AChR\u2010positive gMG forms, our case highlights evidence suggesting that such an approach might be shortsighted and could limit therapeutic options for patients with refractory seronegative gMG. Additionally, introducing more sensitive analytical techniques, exemplified by CBA, may help bridge the gap between seronegative and seropositive patients. This represents an urgent unmet need for gMG patients, as the antibody profile dramatically influences the therapeutic approach.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ene.16306","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T10:10:11Z","timestamp":1715163011000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Overcoming therapeutic challenges: Successful management of a supposedly triple seronegative, refractory generalized myasthenia gravis patient with efgartigimod"],"prefix":"10.1111","volume":"31","author":[{"given":"Benedetta","family":"Sorrenti","sequence":"first","affiliation":[{"name":"Neuroimmunology Research Unit IRCCS Mondino Foundation  Pavia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Laurini","sequence":"additional","affiliation":[{"name":"Neuroimmunology Research Unit IRCCS Mondino Foundation  Pavia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bosco","sequence":"additional","affiliation":[{"name":"Neuroimmunology Research Unit IRCCS Mondino Foundation  Pavia Italy"},{"name":"Institute of Experimental Neurology, Division of Neuroscience, IRCCS San Raffaele Scientific Institute  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla Mirella Maria","family":"Strano","sequence":"additional","affiliation":[{"name":"Neuroimmunology Research Unit IRCCS Mondino Foundation  Pavia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Scarlato","sequence":"additional","affiliation":[{"name":"Neurorehabilitation Unit Quarenghi Clinical Institute  San Pellegrino Terme, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2288-2000","authenticated-orcid":false,"given":"Matteo","family":"Gastaldi","sequence":"additional","affiliation":[{"name":"Neuroimmunology Research Unit IRCCS Mondino Foundation  Pavia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-0479","authenticated-orcid":false,"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[{"name":"Neuroimmunology Research Unit IRCCS Mondino Foundation  Pavia Italy"},{"name":"Vita\u2010Salute San Raffaele University  Milan Italy"},{"name":"Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience IRCCS San Raffaele Scientific Institute  Milan Italy"},{"name":"Neurorehabilitation Unit IRCCS San Raffaele Scientific Institute  Milan Italy"},{"name":"Neurophysiology Service IRCCS San Raffaele Scientific Institute  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2546-4357","authenticated-orcid":false,"given":"Stefano Carlo","family":"Previtali","sequence":"additional","affiliation":[{"name":"Neuroimmunology Research Unit IRCCS Mondino Foundation  Pavia Italy"},{"name":"Institute of Experimental Neurology, Division of Neuroscience, IRCCS San Raffaele Scientific Institute  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri Matteo","family":"Falzone","sequence":"additional","affiliation":[{"name":"Neuroimmunology Research Unit IRCCS Mondino Foundation  Pavia Italy"},{"name":"Institute of Experimental Neurology, Division of Neuroscience, IRCCS San Raffaele Scientific Institute  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,8]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1602678"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn092"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000647"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000596"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27422"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11,617-1"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11,517-w"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01933-1"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200038"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000903308.81107.e2"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2136167"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-329,284"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn131"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2015.04.015"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00212"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577767"},{"issue":"1","key":"e_1_2_8_19_1","first-page":"119","article-title":"The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis","volume":"28","author":"Tice JA","year":"2022","journal-title":"J Manag Care Spec Pharm"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.16306","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T12:19:25Z","timestamp":1717762765000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.16306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,8]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1111\/ene.16306"],"URL":"https:\/\/doi.org\/10.1111\/ene.16306","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,8]]},"assertion":[{"value":"2023-08-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e16306"}}